Relevant bibliographies by topics / Pharmaceutical industry Pharmaceutical biotechnology industry

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Pharmaceutical industry Pharmaceutical biotechnology industry'

Author: Grafiati
Published: 4 June 2021
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical industry Pharmaceutical biotechnology industry.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical industry Pharmaceutical biotechnology industry"

1

Evens, Ronald P. "The Biotechnology Industry." Journal of Pharmacy Practice 11, no. 1 (February 1998): 13–18. http://dx.doi.org/10.1177/089719009801100104.

Full text
Abstract:
Growth and change are the hallmarks of the developing biotechnology industry. Since the first approval of a biological product in 1982, over 40 biologicals, many of them medical breakthroughs, have been brought to market. The majority of biotechnology companies focus on developing human therapeutic agents, but about 25 percent of biotechnology companies focus on the diagnostic area, using monoclonal antibody technology, polymerase chain reaction (PCR) technology, and genetics to provide advances in diagnosis and disease monitoring. Structurally, few biotechnology firms are fully integrated companies with full capabilities in research, development, manufacturing, and sales and marketing. Many pursue strategic alliances with other companies to enhance their capabilities in research, development, and sales and marketing. Research alliances between companies and universities are also frequently used to enhance research capabilities. As the industry has matured, consolidation has occurred, with major pharmaceutical companies purchasing biotechnology companies and biotechnology companies merging to expand their capabilities. Research investment, as a percentage of gross sales, continues to be very high for biotechnology companies compared with traditional pharmaceutical companies. The cost of drug development is high, but the probability of approval appears to be somewhat better in the biotechnology field compared with traditional pharmaceuticals. Today, the biotechnology product pipeline is rich, with between 400 to 700 products in various stages of clinical development. Technology developments beyond recombinant DNA technology and monoclonal antibodies, such as antisense, genomics, and combinatorial chemistry, will lead to additional therapeutic and diagnostic breakthroughs.
APA, Harvard, Vancouver, ISO, and other styles
2

Rubin, Suzie. "Biotechnology and the Pharmaceutical Industry." Cancer Investigation 11, no. 4 (January 1993): 451–57. http://dx.doi.org/10.3109/07357909309018876.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dibner, Mark D. "The pharmaceutical industry: impacts of biotechnology." Trends in Pharmacological Sciences 6 (January 1985): 343–46. http://dx.doi.org/10.1016/0165-6147(85)90158-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gottinger, Hans-Werner, and Celia L. Umali. "The evolution of the pharmaceutical-biotechnology industry." Business History 50, no. 5 (August 5, 2008): 583–601. http://dx.doi.org/10.1080/00076790802246020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

de la Cueva-Méndez, Guillermo, and Dror Seliktar. "Editorial overview: Pharmaceutical biotechnology: Expanding horizons for pharmaceutical biotechnology in industry and academia." Current Opinion in Biotechnology 35 (December 2015): iv—vi. http://dx.doi.org/10.1016/j.copbio.2015.09.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mei, Yan Lan, and Ping Gui. "Study on Bio-Pharmaceutical Industry Development Route and Strategy." Applied Mechanics and Materials 365-366 (August 2013): 1350–54. http://dx.doi.org/10.4028/www.scientific.net/amm.365-366.1350.

Full text
Abstract:
Since recent twenty years, the rapid development of biotechnology has boosted the rapid development of bio-pharmaceutical industry,and bio-pharmaceutical has already stepped into our daily life.Starting from the summary of bio-pharmaceutical industry,the paper makes a SWOT analysis on bio-pharmaceutical industry,making the strengths,weaknesses,opportunities and threats of bio-pharmaceutical industry clear;and focusing on a deep study on the development routes and all stages strategies of bio-pharmaceutical industry in our country.
APA, Harvard, Vancouver, ISO, and other styles
7

Piachaud, Bianca S., and Matthew G. Lynas. "The biotechnology revolution: implications for the pharmaceutical industry." International Journal of Biotechnology 3, no. 3/4 (2001): 350. http://dx.doi.org/10.1504/ijbt.2001.000170.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dibner, M. D., and P. B. Timmermans. "Biotechnology and the pharmaceutical industry. New cardiovascular drugs." Hypertension 8, no. 11 (November 1986): 965–70. http://dx.doi.org/10.1161/01.hyp.8.11.965.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Löffler, A. "Trends in biotechnology: Implications for the pharmaceutical industry." Journal of Medical Marketing 2, no. 4 (September 1, 2002): 345–48. http://dx.doi.org/10.1057/palgrave.jmm.5040092.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bingham, Alph, and Sean Ekins. "Competitive collaboration in the pharmaceutical and biotechnology industry." Drug Discovery Today 14, no. 23-24 (December 2009): 1079–81. http://dx.doi.org/10.1016/j.drudis.2009.10.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharmaceutical industry Pharmaceutical biotechnology industry"

1

Alimov, Azizjon. "Innovations, real options, risk and return : evidence from the pharmaceutical and biotechnology industries /." view abstract or download file of text, 2007. http://proquest.umi.com/pqdweb?did=1421619401&sid=1&Fmt=2&clientId=11238&RQT=309&VName=PQD.

Full text
Abstract:
Thesis (Ph. D.)--University of Oregon, 2007.
Typescript. Includes vita and abstract. Includes bibliographical references (leaves 109-114). Also available for download via the World Wide Web; free to University of Oregon users.
APA, Harvard, Vancouver, ISO, and other styles
2

Gretton, Linda Burak. "The rhetorical helix of the biotechnology and pharmaceutical industries strategies of transformation though definition, description and ingratiation /." Greensboro, N.C. : University of North Carolina at Greensboro, 2007. http://libres.uncg.edu/edocs/etd/1435/umi-uncg-1435.pdf.

Full text
Abstract:
Thesis (Ph.D.)--University of North Carolina at Greensboro, 2007.
Title from PDF t.p. (viewed Oct. 22, 2007). Directed by Nancy Myers; submitted to the Dept. of English. Includes bibliographical references (p. 209-228).
APA, Harvard, Vancouver, ISO, and other styles
3

Otieno, Charles J. "Analysis of strategic alliance deals in the global CNS industry /." Burnaby B.C. : Simon Fraser University, 2006. http://ir.lib.sfu.ca/handle/1892/2741.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nel, Izak Bartholomeus Jacques. "The relationship between global pharmaceutical companies and the biotechnology industry in South Africa : implications for an emerging biotechnology industry in South Africa." Thesis, Stellenbosch : Stellenbosch University, 2003. http://hdl.handle.net/10019.1/53672.

Full text
Abstract:
Mini-study project (MBA)--University of Stellenbosch, 2003.
ENGLISH ABSTRACT: This report reviews the global and South African pharmaceutical and biotechnology industries and provides an overview of the changes taking place within these two industries. It highlights the impact this relationship will have on a developing South African biotechnology industry. Since the 1980s the pharmaceutical industry has experienced phenomenal growth in sales and profits. By the mid 1990s drug sales exceeded USD250 billion. Today the pharmaceutical industry is dominated by multi-national corporations with extensive R&D budgets, widespread use of trademarks and patents and complex commercial process technology. However they face threats from depleted product pipelines, patent expiry on billion dollar drug products, generic competition, increases in drug approval times, costs and price pressures. The entrepreneurial biotechnology industry promises to solve a number of the pharmaceutical industry's problems. In recent years biotechnology companies proved more effective in the development of new molecular entities. They promise individualised therapeutics, novel and more efficacious drug discovery and development of preventative treatments. However the decrease in equity financing after 2001 left almost 40% of biotechnology companies with less than 1 year of R&D funding. The industry experienced losses again in 2002 and the world is divided over the ethical, environmental and economic implications of biotechnological applications. The biotechnology and pharmaceutical industries have a symbiotic but antagonistic relationship. The change in this relationship will hugely affect South Africa's ideals of developing a biotechnology industry. Various diseases plague South Africa including HIV/AIDS, TB, obesity, diabetes, hypertension and infective diseases. These diseases will have a huge impact on South Africa's society. Yet only 10% of global R&D funding is committed to third world diseases and existing drugs and treatments are either not effective or too expensive for developing countries. It is in this situation that biotechnology and the development of a biotechnology industry could playa major role in alleviating South Africa's health burden. South Africa is already capable in first generation biotechnology, but third generation applications holds the most promise. Developing countries face various obstacles and challenges, but all boast well for South Africa. The government has committed R400 million (over a three year period) to utilize South Africa's biotechnology potential. Further, the country has highly skilled researchers, indigenous plant and animal species, a diverse population and a favorable exchange rate (low R&D costs).
AFRIKAANSE OPSOMMING: Die projek ondersoek beide die globale en Suid Afrikaanse farmaseutiese en biotegnologie industrieë. Verder word die veranderinge wat plaasvind in die industrieë onder die soeklig geplaas. Die projek beklemtoon die impak wat die verhouding sal hê op 'n ontwikkelende biotegnologie industrie in Suid Afrika. Die farmaseutiese industrie het sedert die 1980s dubbel syfer groei getoon in omsete en wins. Teen die middel 90's het verkope van farmaseutiese middels US$250 miljard wêreldwyd oorskry. Vandag word die farmaseutiese industrie oorheers deur multi-nasionale korporasies met omvattende navorsing en ontwikkelings begrotings, algemene gebruik van handelsmerkte, patente en komplekse proses-tegnologieë. Ten spyte hiervan word die industrie bedreig deur leë produksie-lyne, verval van patente, miljard dollar farmaseutiese produkte, generiese kompetisie, verlengde produk-goedkeurings periodes en prys-mededinging. Die biotegnologie industrie met sy innoveerende eienskappe beloof om verskeie van die farmaseutiese industrie se probleme op te los. Onlangs het biotegnologie maatskappye getoon dat hulle meer effektief is in die ontwikkeling van nuwe molekulêre eenhede. Biotegnologie beloof nuwe en meer effektiewe produk-ontwikkeling asook beter individuele terapieë en voorkomende behandelings. Die industrie staar finansiële krisisse in die gesig. Slegs 40% van biotegnologie maatskappye het voldoende navorsing en ontwikkelings-kapitaal tot 2004. Dit is hoofsaaklik as gevolg van 'n afname in eienaars-finansiering na 2001. Die industrie as 'n geheel het weereens 'n verlies gelei in 2002 en die wêreld is verdeeld oor die etiese, omgewings en ekonomiese implikasie van biotegnologiese toepassings. Die biotegnologie en farmaseutiese industrieë het 'n simbiotiese maar tog vyandige verhouding. 'n Verandering in die verhouding gaan Suid Afrika se ideale om 'n biotegnologie industrie te skep grootliks beïnvloed. Suid Afrika gaan gebuk onder verskeie siektes insluitende MIVNIGS, TB, vetsugtigheid, diabetes, hipertensie en infeksie siektes. Hierdie siektes het 'n groot impak op Suid Afrika se samelewing. Tog word slegs 10% van die globale navorsings en ontwikkelingsfondse aangewend om 'n oplossing te vind vir derdewêreld siektes. Verder is bestaande produkte en behandelings oneffektief of onbekostigbaar vir ontwikkelde lande. Dit is in sulke gevalle waar biotegnologie en die ontwikkeling van 'n biotegnologie industrie 'n groot rol kan speel in die verligting van Suid Afrika se gesondheids-las. Suid Afrika is vaardig in eerste-generasie biotegnologie, maar wêreld wyd hou derde generasie biotegnologie die meeste belofte in. Die tegnologie is tot op hede onderbenut in Suid Afrika. Ontwikkelende lande staar verskeie uitdagings in die gesig, maar Suid Afrika het talle sterk punte. Die regering het R400 miljoen (oor 'n drie jaar periode) beskikbaar gestel vir die ontwikkeling van Suid Afrika se biotegnologie potensiaal. Die land beskik ook oor navorsers van hoogstande gehalte, onbenutte inheemse plante en dier spesies, 'n diverse populasie en 'n gunstige wisselkoers (lae navorsings en ontwikkelings kostes).
APA, Harvard, Vancouver, ISO, and other styles
5

Vazquez, Toro Guillermo J. "Patent Quality And Company Performance| A Sample within the USA Biotechnology and Pharmaceutical Industry." Thesis, Inter-American University of Puerto Rico (Puerto Rico), 2014. http://pqdtopen.proquest.com/#viewpdf?dispub=3577982.

Full text
Abstract:

This Dissertation investigates the relationship between patent quality and company performance for a sample from the US Biotechnology and Pharmaceutical Industry. The methodology devised comprehensively examines patent worth (patent’s references), patent protection (claims and family patents) and patent quality (references, claims and family patents) to determine their implications on firm leverage (SE, TA), profits (ROE, ROA), and market value (B/M, MCap). The selected sample comprises 1,536 companies, and 285,000 patents from 1999 to 2009. The results show that total revenue just responds to changes in R&D; intensity, and patenting intensity. A 10 percent increase in patent value results in a corresponding increase rate on the market capitalization index for the full sample and a 14 percent increase for the chemicals and allied products group (SIC 28). Increases (10%) in patent protection and quality present average increases of 15 percent on market capitalization for the full sample and 8 percent for the chemicals and allied products group (SIC 28). The medical devices group (SIC 38) results suggest that Mcap increases 10 percent by the same increase in patent value index. Patent protection and quality increases (10%) suggest an average 8 percent increase in Mcap. Results suggest that profits, leverage and market indices respond differently to 10 percent increases in patent value, patent protections and patent quality. The aforementioned effects suggest that the qualitative indexes follow company related market activities and business valuations for the chemical and allied products, and medical devices industrial sectors.

APA, Harvard, Vancouver, ISO, and other styles
6

Possnert, Oliver, and Adam Schön. "A case study research of asymmetrical relationshipsbetween service providers and emerging companieswithin the healthcare industry." Thesis, Uppsala universitet, Institutionen för biologisk grundutbildning, 2018. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-353334.

Full text
Abstract:
This master thesis report aims to highlight the importance ofinterorganizational relationships between experienced serviceproviders and emerging biopharmaceutical (EBP) companies within theSwedish healthcare industry. A shift in innovation strategiesregarding new pharmaceutical- and medical device products hasprompted a paradigm shift within a complex industry wherecollaborations between organisations has become increasinglycrucial. With a better understanding of how these companiesoperates, increased collaboration efforts could result in a fasterand more precise product development with new products reaching themarket improving the health for people around the world. In order toallow experienced service providers to enhance services towards EBPcompanies, a fundamental understanding of how decision makers withinthese EBP companies prefer to conduct relationships is needed. Wehave examined relationship preferences of EBP companies byconducting a qualitative case study through 14 interviews withdecision makers combined with a quantitative conjoint analysis.Eight factors was identified as important for when EBP companiesdecide to engage with a service provider: cost behavior,professional competence, adaptability, communication, personalrelationship, stability, EBP insight and size. The factorsadaptability, personal relationship, cost and size were used in theconjoint analysis to determine their relative importance which showthat adaptability and cost behavior was of the largest importance.With descriptions of each factor, we have provided a meaningfulguide to action of how to address these factors as a serviceprovider. The relationships is largely investigated as relationshipsbetween contract research organizations (as service providers) andEBP companies, but we have created a framework applicable forservice providers within the healthcare industry in general.
APA, Harvard, Vancouver, ISO, and other styles
7

Houston, Chad Allen. "Biotechnology valuation an examination of the drug development pipeline and board of director composition /." View electronic thesis (PDF), 2009. http://dl.uncw.edu/etd/2009-3/r1/houstonc/chadhouston.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rasmussen, Bruce. "Creating and capturing value in the biopharmaceutical sector." full-text, 2008. http://eprints.vu.edu.au/1946/1/Bruce_Rasmussen_PHD_2009.pdf.

Full text
Abstract:
This study addresses the ongoing implications of the realignment of the pharmaceutical industry knowledge base – from small molecule methods to new biomedical technologies – for the competitive positions of traditional pharmaceutical companies and biopharmaceutical start-ups. The theoretical approach draws on the modern theory of the firm and related concepts, to define and develop the concept of the business model. This is employed to guide the empirical analysis, which utilises a combination of data analyses and case studies based on several sources, including detailed company reports and alliance databases. The thesis analyses how the pharmaceutical companies have successfully adjusted their business models to meet the challenge of biotechnology and so retain their powerful position in the industry. Central to this has been the breadth and depth of knowledge transfer through alliance formation. Not only has this been critical to the adjustment process for the large pharmaceutical companies but also for the development of the many biopharmaceutical start ups. Nonetheless the business models of these smaller companies have many weaknesses, which have led to the erosion of the value of their initial strategic assets. Despite the poor financial performance of the vast majority of these firms, the biopharmaceutical sector as a whole has created significant value. This has been captured disproportionately by a handful of large fully integrated biopharmaceutical firms and, to a lesser extent, by the largest dozen pharmaceutical firms.
APA, Harvard, Vancouver, ISO, and other styles
9

Rasmussen, Bruce. "Creating and capturing value in the biopharmaceutical sector." Thesis, full-text, 2008. https://vuir.vu.edu.au/1946/.

Full text
Abstract:
This study addresses the ongoing implications of the realignment of the pharmaceutical industry knowledge base – from small molecule methods to new biomedical technologies – for the competitive positions of traditional pharmaceutical companies and biopharmaceutical start-ups. The theoretical approach draws on the modern theory of the firm and related concepts, to define and develop the concept of the business model. This is employed to guide the empirical analysis, which utilises a combination of data analyses and case studies based on several sources, including detailed company reports and alliance databases. The thesis analyses how the pharmaceutical companies have successfully adjusted their business models to meet the challenge of biotechnology and so retain their powerful position in the industry. Central to this has been the breadth and depth of knowledge transfer through alliance formation. Not only has this been critical to the adjustment process for the large pharmaceutical companies but also for the development of the many biopharmaceutical start ups. Nonetheless the business models of these smaller companies have many weaknesses, which have led to the erosion of the value of their initial strategic assets. Despite the poor financial performance of the vast majority of these firms, the biopharmaceutical sector as a whole has created significant value. This has been captured disproportionately by a handful of large fully integrated biopharmaceutical firms and, to a lesser extent, by the largest dozen pharmaceutical firms.
APA, Harvard, Vancouver, ISO, and other styles
10

Pavúk, Šimon. "Aplikácia investičnej analýzy na biotechnologicko- farmaceutický sektor." Master's thesis, Vysoká škola ekonomická v Praze, 2010. http://www.nusl.cz/ntk/nusl-76239.

Full text
Abstract:
The principal aim of this thesis is to describe methods of fundamental analysis of three major companies from sectors of Biotechnology and Pharmaceuticals, namely Johnson & Johnson, Pfizer and Amgen. Among used methods we are able to find 2 -- stage discounted cashlow models Free-cashflow-to-equity FCFE and Free-cashflow-to-firm FCFF, Gordon's dividend discount model a relative valuation methods using P/E, P/BV and P/S. Descriptive part of this thesis describes legal and regulatory environment, which has significant impact on the development process of new innovative drugs and therapies. Further it sets investment recommendations and looks closer at investment opportunities in biotechnological companies.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Pharmaceutical industry Pharmaceutical biotechnology industry"

1

Welch, Mary F., Esther K. Palevsky, Diana E. Kole, and Dawn J. Trebec. Biotechnology pharmaceuticals. Cleveland: Freedonia Group, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Misch, Kelly, and William D. Martineau. Biotechnology pharmaceuticals. Cleveland: Freedonia Group, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

J, Groves M., ed. Pharmaceutical biotechnology: Fundamentals and essentials. Buffalo Grove, Ill: Interpharm Press, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Werth, Barry. The billion-dollar molecule: One company's quest for the perfect drug. New York: Simon & Schuster, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Werth, Barry. The billion-dollar molecule: One company's quest for the perfect drug. New York: Simon & Schuster, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Friedman, Rebecca L., and William D. Martineau. Biotechnology in pharmaceuticals. Cleveland: Freedonia Group, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Business development for the biotechnology and pharmaceutical industry. Aldershot, Hants, England: Gower, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Anisfeld, Michael H. International biotechnology, bulk chemical, and pharmaceutical GMPs. 5th ed. Denver, Colo: Interpharm Press, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Alberta. Alberta Economic Development and Tourism. Technology Development Branch., ed. Alberta biotechnology and pharmaceutical directory. Edmonton, Alta: Alberta Economic Development and Tourism, Technology Development Branch, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zhongguo sheng wu zhi yao chan ye jing zheng li yan jiu. Shanghai Shi: Shanghai cai jing da xue chu ban she, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Pharmaceutical industry Pharmaceutical biotechnology industry"

1

Resnik, David B. "Patents in the Pharmaceutical Biotechnology Industry: Legal and Ethical Issues." In Pharmaceutical Biotechnology, 269–84. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2012. http://dx.doi.org/10.1002/9783527632909.ch12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Resnik, David B. "Patents in the Pharmaceutical Biotechnology Industry: Legal and Ethical Issues." In Pharmaceutical Biotechnology, 187–200. Weinheim, FRG: Wiley-VCH Verlag GmbH & Co. KGaA, 2005. http://dx.doi.org/10.1002/3527602410.ch10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kadow, John F., Nicholas A. Meanwell, Kyle J. Eastman, Kap-Sun Yeung, and Albert J. DelMonte. "Chemistry in the Pharmaceutical Industry." In Handbook of Industrial Chemistry and Biotechnology, 531–79. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-52287-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kadow, John F., Nicholas A. Meanwell, Kyle J. Eastman, Kap-Sun Yeung, and Joseph Payack. "Chemistry in the Pharmaceutical Industry." In Handbook of Industrial Chemistry and Biotechnology, 391–418. Boston, MA: Springer US, 2012. http://dx.doi.org/10.1007/978-1-4614-4259-2_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Poindexter, Graham S., Yadagiri Pendri, Lawrence B. Snyder, Joseph P. Yevich, and Milind Deshpande. "Chemistry in the Pharmaceutical Industry." In Kent and Riegel’s Handbook of Industrial Chemistry and Biotechnology, 404–30. Boston, MA: Springer US, 2007. http://dx.doi.org/10.1007/978-0-387-27843-8_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Armenante, P. M., and A. C. Kirpekar. "Sterilization in the pharmaceutical and biotechnology industry." In Handbook of Downstream Processing, 261–308. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-009-1563-3_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Giri, Sib Sankar. "Application of Microbial Biosurfactants in the Pharmaceutical Industry." In Environmental and Microbial Biotechnology, 251–69. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-6607-3_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lamottke, Kai, Nicole Feling, and Christian Haug. "Bicoll — The First Sino-German Biotechnology Company." In The Chemical and Pharmaceutical Industry in China, 189–98. Berlin, Heidelberg: Springer Berlin Heidelberg, 2005. http://dx.doi.org/10.1007/3-540-26561-9_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ramani, Shyama V., and M. S. Venkataramani. "Biotechnology and the Indian Pharmaceutical Industry Integration and Impact." In China and India, 181–206. London: Palgrave Macmillan UK, 1999. http://dx.doi.org/10.1007/978-0-333-99508-2_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Boddu, Ramya Sree, and K. Divakar. "Metagenomic Insights into Environmental Microbiome and Their Application in Food/Pharmaceutical Industry." In Microbial Biotechnology, 23–38. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-10-7140-9_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical industry Pharmaceutical biotechnology industry"

1

MATOS, Murilo Montanari de, and Sérgio Robles Reis de QUEIROZ. "Technical Change and the Incorporation of Biotechnology in the Pharmaceutical Industry." In II Encontro Nacional de Economia Industrial e Inovação. São Paulo: Editora Blucher, 2017. http://dx.doi.org/10.5151/enei2017-06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sevick-Muraca, Eva M., and Steven Richter. "Frequency-Domain Photon Migration for Applications in the Biotechnology, Chemical, and Pharmaceutical Industry." In Biomedical Optical Spectroscopy and Diagnostics. Washington, D.C.: OSA, 2000. http://dx.doi.org/10.1364/bosd.2000.sue7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Li, Yinuo. "The impact of biotechnology and pharmaceutical industries on regional economies during the epidemic period." In 2021 3rd International Conference on Economic Management and Cultural Industry (ICEMCI 2021). Paris, France: Atlantis Press, 2021. http://dx.doi.org/10.2991/assehr.k.211209.323.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chen, Hsin-Po, Chia-Nan Wang, and Ming-Hsien Hsueh. "The Critical Success Factors of Biotechnology and Pharmaceutical Industry in SIAT---Integration Entrepreneur, Entrepreneurial Opportunity and Entrepreneurial Resource Perspective." In 2015 International Conference on Management Science and Innovative Education. Paris, France: Atlantis Press, 2015. http://dx.doi.org/10.2991/msie-15.2015.60.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Menezes, Thiago, Carlos Gomes, Walter Santos Junior, Jorge Magalhães, and Gabriel Ferreira. "Agile Method of Qualification for Equipment at Pharmaceutical Industry of Biotechnology: A Case Study at Bio-Manguinhos ‘s Henrique Penna Center." In IV International Symposium on Immunobiologicals & VII Seminário Anual Científico e Tecnológico. Instituto de Tecnologia em Imunobiológicos, 2019. http://dx.doi.org/10.35259/isi.sact.2019_32771.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bhandigani, Rutuja, Nikhil Ujjwal, Shubham Pattekar, and Amit Sadanand Savyanavar. "Enterprise Optimization in Pharmaceutical Industry." In 2021 International Conference on Smart Generation Computing, Communication and Networking (SMART GENCON). IEEE, 2021. http://dx.doi.org/10.1109/smartgencon51891.2021.9645744.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Potdar, Manohar, Elizabeth Chang, and Vidyasagar Potdar. "Applications of RFID in Pharmaceutical Industry." In 2006 IEEE International Conference on Industrial Technology. IEEE, 2006. http://dx.doi.org/10.1109/icit.2006.372726.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Scott, Steve L. "Successful machine vision for the pharmaceutical industry." In Photonics East '95, edited by Bruce G. Batchelor, Susan S. Solomon, and Frederick M. Waltz. SPIE, 1995. http://dx.doi.org/10.1117/12.223997.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Stone, A., and K. Flamm. "Knowledge and productivity in the pharmaceutical industry." In 2009 Atlanta Conference on Science and Innovation Policy. IEEE, 2009. http://dx.doi.org/10.1109/acsip.2009.5367866.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Alemuda, Fariz, Ibnu Alinursafa, Daniel Adrianto, and I. Ketut Agung Enriko. "Incorporating one M2M Platform to Pharmaceutical Industry." In 2019 IEEE International Conference on Internet of Things and Intelligence System (IoTaIS). IEEE, 2019. http://dx.doi.org/10.1109/iotais47347.2019.8980431.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pharmaceutical industry Pharmaceutical biotechnology industry"

1

Greene, Anne, Kelly Waldron, and Nuala Calnan. Quality Risk Management: State of the Industry—Part 1. Has the Industry Realized the Full Value of ICH Q9? Institute of Validation Technology, January 2014. http://dx.doi.org/10.1080/21507090.ar1152014agkwnc-qrmsoi.

Full text
Abstract:
This paper summarizes research designed to characterize the current state of pharmaceutical and biotechnology industries with respect to the adoption of Quality Risk Management as per ICH Q9. The research supports the hypotheses that the full value of QRM with respect to product quality and patient safety has not yet been realized. In addition, industry appears to be lagging behind regulatory expectations with respect to QRM maturity, indicating that current approaches to QRM require significant improvement.
APA, Harvard, Vancouver, ISO, and other styles
2

Lang, Heather, Tim Koder, and Christopher Winchester. Is pharmaceutical industry research posted as preprints? Oxford PharmaGenesis, April 2018. http://dx.doi.org/10.21305/ismppus2018.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Morton, Fiona M. Scott. Entry Decisions in the Generic Pharmaceutical Industry. Cambridge, MA: National Bureau of Economic Research, September 1997. http://dx.doi.org/10.3386/w6190.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Byrski, Dennis, Fabian Gaessler, and Matthew Higgins. Market Size and Research: Evidence from the Pharmaceutical Industry. Cambridge, MA: National Bureau of Economic Research, May 2021. http://dx.doi.org/10.3386/w28858.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dubois, Pierre, Ashvin Gandhi, and Shoshana Vasserman. Bargaining and International Reference Pricing in the Pharmaceutical Industry. Cambridge, MA: National Bureau of Economic Research, May 2022. http://dx.doi.org/10.3386/w30053.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Muqtadiroh, Feby Artwodini, Mauridhi Hery Purnomo, and I. Ketut Eddy Purnama. AI in the pharmaceutical industry promises cheaper, faster, better drugs. Edited by Ria Ernunsari and Sara Phillips. Monash University, August 2022. http://dx.doi.org/10.54377/8090-55bb.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Muqtadiroh, Feby Artwodini, Mauridhi Hery Purnomo, and I. Ketut Eddy Purnama. AI in the pharmaceutical industry promises cheaper, faster, better drugs. Edited by Ria Ernunsari and Sara Phillips. Monash University, August 2022. http://dx.doi.org/10.54377/8090-55bb.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Acemoglu, Daron, and Joshua Linn. Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry. Cambridge, MA: National Bureau of Economic Research, October 2003. http://dx.doi.org/10.3386/w10038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Atella, Vincenzo, Jay Bhattacharya, and Lorenzo Carbonari. Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy. Cambridge, MA: National Bureau of Economic Research, December 2008. http://dx.doi.org/10.3386/w14567.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Panayi, Antonia, Slavka Baronikova, Jim Purvis, Eric Southam, Julie Beeso, and Christopher Winchester. Disclosing the results of clinical trials: how is the pharmaceutical industry doing? Oxford PharmaGenesis, June 2018. http://dx.doi.org/10.21305/evli2018.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmaceutical industry Pharmaceutical biotechnology industry' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography